Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Artificial Organs
|
January 13, 2005
Intra-aortic balloon pumping: does posture matter?
Ashraf W Khir, Susana Price, Colin Hale, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
September 12, 2021
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva
Alieu Amara, Sujan Dilly Penchala, Laura Else, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
May 6, 2023
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
Elizabeth Challenger, Sujan Dilly Penchala, Colin Hale, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
April 23, 2024
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells
Elizabeth Challenger, Sujan Dilly-Penchala, Colin Hale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard FitzGerald, Laura Dickinson, Laura Else, et al.
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics
|
October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Artificial Organs
|
January 13, 2005
Intra-aortic balloon pumping: does posture matter?
Ashraf W Khir, Susana Price, Colin Hale, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
September 12, 2021
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva
Alieu Amara, Sujan Dilly Penchala, Laura Else, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
May 6, 2023
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
Elizabeth Challenger, Sujan Dilly Penchala, Colin Hale, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
April 23, 2024
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells
Elizabeth Challenger, Sujan Dilly-Penchala, Colin Hale, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 10, 2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Richard FitzGerald, Laura Dickinson, Laura Else, et al.
The Journal of Antimicrobial Chemotherapy
|
June 16, 2026
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye H Khoo, Richard FitzGerald, Christopher J Edwards, et al.
Clinical Pharmacology and Therapeutics
|
March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics
|
October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
The Lancet. Infectious Diseases
|
October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Communications
|
November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
I'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Page
of 2